Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deslorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.74 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690690 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29588982 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29750348 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL25353366 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL172917 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL25418953 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL14190828 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL29350981 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29833896 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL28615809 | 0.99 | GNRHR (0.73) | GNRHRABCC2PTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3949951-B1 | SUSTAINED-RELEASE MICROPARTICLES CONTAINING DESLORELIN, AND PREPARATION METHOD THEREFOR | INVENTAGE LAB INC (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20260014227-A1 | DESLORELIN USE IN CHEMICAL CASTRATION OF A NON-HUMAN MAMMAL RELATED TO PK/PD INTERACTION | VIRBAC (FR) | 2026-01-15 | — | — | US | claimed |
| US-20260014090-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | UNIV GEORGIA (US) | 2026-01-15 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007716-A1 | DESLORELIN FOR ATTENUATION OF ANIMAL URINE ODOR | VIRBAC (FR) | 2026-01-08 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-1994026207-A1 | METHODS AND FORMULATIONS FOR USE IN TREATING BENIGN GYNECOLOGICAL DISORDERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-11-24 | — | — | WO | claimed |
| US-5340584-A | Gonadotropin hormone releasing hormone, an estrogenic composition and a progestogen | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| US-5340585-A | Administering slow release formulation of gonadotropin hormone releasing hormone and estrogen | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| EP-0609345-A1 | BIOCOMPATIBLE IMPLANT FOR THE TIMING OF OVULATION IN MARES | PEPTIDE TECHNOLOGY LTD (AU) | 1994-08-10 | — | — | EP | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| WO-1993015722-A1 | CONTROLLED DELIVERY OF PHARMACEUTICALS FROM PREFORMED POROUS MICROPARTICLES | SYNTEX (USA) INC. (US) | 1993-08-19 | — | — | WO | claimed |
| US-5211952-A | Drug delivery of gonadotropin hormone releasing hormones for time release | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| WO-1993007833-A1 | BIOCOMPATIBLE IMPLANT FOR THE TIMING OF OVULATION IN MARES | PEPTIDE TECHNOLOGY LIMITED (AU) | 1993-04-29 | — | — | WO | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |